The Essence of Cell Therapy for the Heart Presented to Top Thai Cardiologists
Top Thai cardiologists gather for the first time for a symposium in cell therapy
Bangkok, , October 27th, 2004 – The science of cell therapy and details about the ongoing clinical trial using endothelial progenitor cells for severe ischemic heart disease were presented to the top Thai cardiologists for the first time. The event, hosted by Theravitae Co., Ltd., the company sponsoring the clinical trial at the
Associate Professor Damras Tresukosol, MD, Head of the Invasive Unit, Director of the Catheterization Laboratory of Her Majesty’s
Professor Suphachai Chaithiraphan, MD, President of the Heart Association of Thailand and President of the Thai Atherosclerosis Society, chaired the symposium.
The cell therapy clinical trial, sponsored by Theravitae, is now enrolling patients with recurring chest pain on maximal medical therapy which are eligible according to certain inclusion or exclusion criteria (http://www.theravitae.com/eligibility.php). Eligible patients should be referred to the cardiology department at
TheraVitae is an emerging biotechnology company with the prime mission to offer novel, cutting edge cell therapies to patients worldwide. Initially, the Company focuses on the treatment of cardiovascular disorders. Other cell-based treatments for severe disorders, such as glaucoma and age-related macular degeneration, are under development.
For more information:
Last updated on: 27/08/2010
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.